Michel Vounatsos

Board Member

Mr. Vounatsos served as Chief Executive Officer and member of the Board of Directors of Biogen, Inc. from January 2017 to November 2022, after serving as Executive Vice President and Chief Commercial Officer in 2016. Prior to joining Biogen, Mr. Vounatsos held various roles of increasing responsibility at Merck & Co. from 1996 to 2016. Mr. Vounatsos served as President, Primary Care & Merck Customer Centricity responsible for strategic and business development decisions to grow Merck’s multibillion primary care business. Mr. Vounatsos previously held commercial leadership positions across China and Europe for Merck. Mr. Vounatsos was President of MSD China from 2008 to 2012. During this time, Mr. Vounatsos created a long-term strategy and several strategic alliances which helped MSD China significantly increase performance. Prior to Merck, Mr. Vounatsos held management positions at Ciba-Geigy, a pharmaceutical company, from 1990 to 1996. Mr. Vounatsos has served as a member of the Board of Directors and Audit Committee of Revvity, Inc., a global scientific technology and life science research company, since 2020 and as chair of the Nominating and Corporate Governance Committee since October 2022. He holds a board position at Zai Labs, serving as a member of R&D and as chair of the Commercial Committee. He also serves on the Advisory Board of Tsinghua University School of Pharmaceutical Sciences in Beijing, China and as Chairman of the Supervisory Board of Liryc, the Electrophysiology and Heart Modeling Institute at the University of Bordeaux.

Mr. Vounatsos received an MBA from HEC School of Management in Paris, France and his C.S.C.T. certificate in Medicine from Université Victor Segalen, Bordeaux II, also in France.